关于mGlu4调节器专利的更新:2017年至今
Fahad Imtiaz Rahman1,2, Thomas M Webster1, Corey R Hopkins1,3
1Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Expert opinion on therapeutic patents
|February 13, 2025
概括
积极的全调节剂 (PAMs) 向甲基酸盐受体4 (mGluR4) 显示出治疗大脑疾病的潜力. 对mGluR4 PAMs的临床试验结果对于未来的治疗开发至关重要.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 甲基增生谷氨酸受体4 (mGluR4) 在神经递质释放和突触可塑性中起作用.
- mGluR4的失调与神经退行性疾病,精神疾病和其他大脑疾病有关.
- mGluR4是帕金森病,多发性硬化症和慢性疼痛等疾病的新兴治疗点.
研究的目的:
- 从2017年到2024年,审查关于mGluR4阳性全调节器 (PAMs) 的专利和文献.
- 总结主要的示例化合物,结构-活性关系 (SAR) 和生物数据.
- 讨论mGluR4 PAM开发的关键发现和未来方向.
主要方法:
- 使用SciFinder,谷歌专利和PubMed进行文献和专利搜索.
- 分析示例化合物,SAR和从获取的来源的生物数据.
- 综合发现,评估mGluR4 PAMs的现状和未来前景.
主要成果:
- 几种mGluR4 PAM已经在专利和文献中得到了说明.
- 两种化合物已经进入早期临床试验阶段.
- 一个临床试验 (Prexton Therapeutics) 由于疗效问题而失败;另一个 (Appello Pharmaceuticals) 的结果正在等待.
结论:
- mGluR4 PAMs代表了各种神经和精神疾病的有前途的治疗策略.
- 目前正在进行的临床试验的结果将对确定mGluR4 PAMs在药物开发中的未来至关重要.
- 需要进一步的研究和开发来克服有效性挑战,并推进mGluR4向治疗.
更多相关视频
04:48A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
Published on: July 10, 2018
9.2K
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.6K
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
204
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
204
01:27Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K